Syngene International declares ₹1.25 dividend, appoints new directors

2 min read     Updated on 30 Jul 2026, 12:15 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Syngene International Limited held its 33rd AGM on July 29, 2026, declaring a final dividend of ₹1.25 per share for FY26. The meeting approved the appointment of S.R. Batliboi & Associates LLP as statutory auditors, replacing B S R & Co. LLP. Shareholders also appointed Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors and reappointed Professor Catherine Rosenberg.

powered bylight_fuzz_icon
46896334

*this image is generated using AI for illustrative purposes only.

Syngene International Limited declared a final dividend of ₹1.25 per equity share for the financial year ended March 31, 2026, during its 33rd Annual General Meeting (AGM) held on July 29, 2026. The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM), also approved significant changes to the Board of Directors and the appointment of a new statutory auditor, marking a transition in the company’s governance structure for the upcoming fiscal period.

The AGM commenced at 3:31 pm (IST) with 117 members present. The proceedings were overseen by Ms. Kiran Mazumdar-Shaw, Executive Chairperson, and Mr. Siddharth Mittal, Managing Director and Chief Executive Officer. In compliance with the Companies Act, 2013 and SEBI Listing Regulations, the company facilitated remote e-voting from July 24, 2026, to July 28, 2026, allowing shareholders to cast their votes on all nine resolutions proposed.

Key Resolutions Approved

The ordinary business items included the adoption of the audited standalone and consolidated financial statements for FY26. Alongside the financial statements, the Board recommended the final dividend payout. The special business agenda focused on board composition and auditor appointments.

Resolution Category Key Outcome Details
Dividend Final Dividend Declared ₹1.25 per equity share for FY26
Auditor Appointment New Statutory Auditor S.R. Batliboi & Associates LLP appointed; B S R & Co. LLP outgoing
Board Appointments Independent Directors Dr. Vijaya Chandru and Dr. Arun Chandavarkar appointed
Board Reappointments Director Rotation Professor Catherine Rosenberg retired by rotation and reappointed
Management MD & CEO Approval Mr. Siddharth Mittal’s appointment and remuneration approved

Governance and Leadership Changes

A notable shift occurred in the audit function, with M/S S.R. Batliboi & Associates LLP (ICAI Firm Registration Number: 101049W/E300004) appointed as the Statutory Auditors, succeeding B S R & Co. LLP. Mr. Ankit Mittal, Partner at S.R. Batliboi & Associates LLP, attended the meeting as the incoming auditor.

The Board composition was updated with the appointment of Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors. Ms. Vinita Bali was recommended for appointment as a Non-Executive Director. Professor Catherine Rosenberg, who retired by rotation, was reappointed as a director. The remuneration payable to Mr. Siddharth Mittal in his capacity as Managing Director and CEO was also approved by the shareholders.

Analytical Observation

The simultaneous appointment of two new Independent Directors and a change in statutory auditors suggests a strategic refresh of the company’s oversight mechanisms. This aligns with regulatory expectations for enhanced corporate governance in listed entities. The declaration of a consistent final dividend of ₹1.25 per share, despite the transition in audit firms, signals management’s confidence in the company’s cash flow stability and commitment to shareholder returns for FY26.

Historical Stock Returns for Syngene International

1 Day5 Days1 Month6 Months1 Year5 Years
+1.25%+0.24%-4.58%-13.75%-40.01%-34.08%

How might the transition from B S R & Co. LLP to S.R. Batliboi & Associates LLP impact Syngene's future audit timelines or compliance reporting standards?

What specific expertise do the newly appointed Independent Directors, Dr. Vijaya Chandru and Dr. Arun Chandavarkar, bring that could influence Syngene's strategic direction in the CRO sector?

Given the consistent dividend payout, does management anticipate any changes to capital allocation strategies or investment in R&D for the upcoming fiscal year?

like19
dislike

Syngene International accepts Kush Parmar's resignation as Independent Director

1 min read     Updated on 29 Jul 2026, 10:58 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Syngene International Limited accepted Kush Parmar's resignation as Independent Director effective July 29, 2026, due to his US-based commitments. Parmar also steps down from the Risk Management and Science and Technology Committees. The move complies with SEBI Listing Regulations, with no other material reasons cited.

powered bylight_fuzz_icon
46891667

*this image is generated using AI for illustrative purposes only.

Syngene International has accepted the resignation of Kush Parmar as an Independent Director on its Board, effective from the close of business hours on July 29, 2026. The change follows Parmar’s decision to step down due to increasing commitments in the United States and his inability to devote sufficient time to the company while residing outside India. Consequently, Parmar will also cease to be a member of the Risk Management Committee and the Science and Technology Committee.

The Board placed the resignation on record pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III. The disclosure was made to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). The company confirmed that there are no other material reasons for the resignation beyond those stated in Parmar’s letter.

Resignation Details

Kush Parmar, identified by DIN 09212020, tendered his resignation citing personal professional constraints. His address is listed as 230 Dudley Rd., Newton, MA 02459, USA. The resignation was accepted by the Board on July 29, 2026.

Particulars Details
Name Kush Parmar
DIN 09212020
Position Independent Director
Effective Date July 29, 2026
Reason Increasing commitments in the USA; residence outside India
Committee Memberships Ceased Risk Management Committee, Science and Technology Committee

Regulatory Compliance

The disclosure aligns with SEBI Master Circular no. SEBI/HO/49/14/14(7)2025-CFD-PoD2/I/3762/2026 dated January 30, 2026. Under Para A(7B) of Part A of Schedule III of the SEBI Listing Regulations, Parmar confirmed that he holds no directorships in other listed entities at the time of his resignation. He further affirmed that there are no undisclosed material reasons for his departure.

The Board expressed appreciation for Parmar’s contributions, independent judgment, and commitment during his tenure. The full details of the resignation, including the letter of resignation, have been made available on the company’s website.

Historical Stock Returns for Syngene International

1 Day5 Days1 Month6 Months1 Year5 Years
+1.25%+0.24%-4.58%-13.75%-40.01%-34.08%

Has Syngene International initiated the search for a replacement Independent Director to fill the vacancy on the Risk Management and Science and Technology Committees?

How might the loss of Kush Parmar's expertise in science and technology impact Syngene's strategic oversight of its R&D pipeline?

Are there any pending regulatory approvals or board decisions that could be delayed due to the temporary reduction in independent director count?

like15
dislike

More News on Syngene International

1 Year Returns:-40.01%